How repotrectinib targets ROS1-positive cancer
Repotrectinib is a targeted cancer drug designed to shut down abnormal signaling caused by ROS1 gene fusions. In ROS1-positive cancers, tumor cells often carry ROS1 fusion proteins that act like a constantly “on” growth signal. Repotrectinib binds to the ROS1 kinase and inhibits its activity, which stops downstream pathways that drive cell growth and survival.[1]
What pathways does ROS1 inhibition affect?
When ROS1 is active, it triggers signaling cascades that support proliferation and help tumors evade normal controls on cell division. By inhibiting ROS1 kinase activity, repotrectinib reduces those downstream growth and survival signals, leading to slower tumor growth and tumor cell death.[1]
Which cancers are ROS1-positive and where repotrectinib is used
ROS1 fusions are most commonly found in certain lung cancers, including non-small cell lung cancer (NSCLC). In these ROS1-positive tumors, repotrectinib is used to target the fusion-driven driver that keeps the cancer growing.[1]
Why ROS1-targeted therapy can work even when the tumor spreads
ROS1 fusions are “driver” alterations, meaning they directly power the cancer phenotype. Targeting the kinase that produces those signals can work across tumor sites because the same driver mechanism can be present throughout the cancer’s metastatic deposits.[1]
What resistance can look like (and why it matters)
As with many targeted kinase inhibitors, tumors can develop resistance, including by changes that reduce the drug’s ability to bind the kinase or that activate bypass growth pathways. That resistance is one reason researchers and clinicians watch for how long responses last and whether next-line options are needed.[1]
Sources
- DrugPatentWatch.com – repotrectinib (ROS1) information: https://www.drugpatentwatch.com/